LncRNA GALNT5 uaRNA promotes cisplatin resistance in colorectal cancer via NF- κB/MDR1/MRP1/ pathway

To clarify the function of long non-coding RNA (lncRNA) GALNT5 uaRNA in cisplatin resistant colorectal cancer and its potential mechanism. The expression levels were also detected in cisplatin resistant colorectal cancer cell lines (HCT116/DDP and HT29/DDP cells) and sensitive colorectal cancer cell lines. The effects of GALNT5 uaRNA on apoptosis of HCT116/DDP and HT29/DDP cells were examined by flow cytometry assay respectively. The protein levels of drug resistance related genes influenced by GALNT5 uaRNA were detected by Western blot. The cells of siNC, sIGALNT5 uaRNA, Vector and GALNT5 uaRNA cells groups from HCT116/DDP and HT29/DDP cells were injected into dorsal flanks of the mice repectively. Higher GALNT5 uaRNA expression was observed in HCT116/DDP and HT29/DDP cells relative to that of their parental cells. The apoptotic rate increased in HCT116/DDP and HT29/DDP cells with GALNT5 uaRNA knockdown compared to the cells with control group. Furthermore, the expression levels of MDR1, MRP1 and p-NF-κB were decreased in HCT116/DDP and HT29/DDP cells with GALNT5 uaRNA knockdown compared to the cells with control group. The apoptotic rate decreased in HCT116/DDP and HT29/DDP cells with GALNT5 uaRNA overexpression. Furthermore, the expression levels of MDR1, MRP1 and p-NF-κB were increased in HCT116/DDP cells with GALNT5 uaRNA overexpression compared to the cells with control group. The tumors in the HCT116/DDP/siGANLNT5 uaRNAgroup were smaller and lighter than those in the HCT116/DDP/siNC. In a word GALNT5 uaRNA promotes cisplatin resistance by MDR1/MRP1/NF-κB pathway.